![]() Switch from twice daily NPH insulin to Semglee ®: To reduce the risk of nocturnal and early morning hypoglycaemia, daily dose of once daily basal insulin should be reduced by 20-30% during the first weeks of treatment. Switch from other insulins to Semglee ® When switching from a treatment regimen with an intermediate or long acting insulin to a regimen with Semglee ®, a change of the dose of the basal insulin may be required and the concomitant antidiabetic treatment may need to be adjusted (dose and timing of additional regular insulins or fast acting insulin analogues or the dose of oral antidiabetic medicinal products). For children below 2 years of age the safety and efficacy of Semglee ® have not been established. Paediatric population: For adolescents and children aged 2 years and older patients, the dose regimen (dose and timing) should be individually adjusted. Hepatic impairment: insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism. Renal impairment: insulin requirements may be diminished due to reduced insulin metabolism. Special population: Elderly population (≤ 65 years old): progressive deterioration of renal function may lead to a steady decrease in insulin requirements. The potency of Semglee ® is stated in units and these units are exclusive to Semglee ®. In patients with type 2 diabetes mellitus, Semglee ® can also be given together with orally active antidiabetic medicinal products. The dose regimen (dose and timing) should be individually adjusted. The pre filled pen delivers insulin in increments of 1 unit up to a maximum single dose of 80 units. ![]() It should be administered once daily at any time but at the same time each day. Dosage and administration: Semglee ® (insulin glargine) has a prolonged duration of action. ![]() Each pen contains 3 ml of solution for injection, equivalent to 300 units. Presentation: Each ml contains 100 units insulin glargine* (equivalent to 3.64 mg). Indication: Semglee ® is indicated in the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. You may end your participation in Janssen CarePath at any time by calling 888-XARELTO (88).Please refer to Summary of Product Characteristics (SmPC) before prescribing. Void where prohibited, taxed, or limited by law. Offer good only in the United States and its territories. This program offer may not be used with any other coupon, discount, prescription savings card, free trial, or other offer. Janssen Pharmaceuticals, Inc., will not share your information with anyone else except where legally allowed. We may also use the information you give us to learn more about the people who use XARELTO ® and to improve the information we give them. This information is needed for Janssen Pharmaceuticals, Inc., and our service providers to enroll you in the Janssen CarePath Savings Program. These transactions include rebates and any funds placed on the card or balance remaining on the card.īefore you enroll in the program, you will be asked to provide personal information that may include your name, address, phone number, email address, and information related to your prescription medication insurance and treatment. By using the Savings Program card, you confirm that you have read, understood, and agree to the program requirements on this page, and you are giving permission for information related to your Savings Program transactions to be shared with your healthcare provider(s). To use this program, you must follow any health plan requirements, including telling your health plan how much co-payment support you get from this program. The program may change or end without notice, including in specific states. Program terms will expire at the end of each calendar year. You must meet the program requirements every time you use the card. You may not seek payment for the value received from this program from any health plan, patient assistance foundation, flexible spending account, or healthcare savings account. Examples of these programs are Medicare, Medicaid, TRICARE, Department of Defense, and Veterans Administration. This program is not for people who use any state or federal government-funded healthcare program. This includes plans from the Health Insurance Marketplace. This program is only for people using commercial or private health insurance for their Janssen medication.Use commercial or private health insurance for XARELTO ®Īre being treated with XARELTO ®, except if you are prescribed XARELTO ® 10 mg because of a recent non-surgical hospital discharge or because you have recently undergone hip or knee replacement surgery You may be eligible for the Janssen CarePath Savings Program if you:
0 Comments
Leave a Reply. |